Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and lowers the price target from $18 to $16.
July 19, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mizuho analyst Uy Ear maintains a Neutral rating on Sage Therapeutics and lowers the price target from $18 to $16.
The lowered price target from $18 to $16 by Mizuho suggests a less optimistic outlook for Sage Therapeutics, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100